<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Res Notes</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Res Notes</journal-id>
      <journal-title-group>
        <journal-title>BMC Research Notes</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1756-0500</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25125318</article-id>
      <article-id pub-id-type="pmc">4143581</article-id>
      <article-id pub-id-type="publisher-id">3066</article-id>
      <article-id pub-id-type="doi">10.1186/1756-0500-7-529</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Complete remission of paraneoplastic vanishing bile duct syndrome after the successful treatment of Hodgkin&#x2019;s lymphoma: a case report and review of the literature</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Rota Scalabrini</surname>
            <given-names>Delia</given-names>
          </name>
          <address>
            <email>delia.rotascalabrini@ircc.it</email>
          </address>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Caravelli</surname>
            <given-names>Daniela</given-names>
          </name>
          <address>
            <email>daniela.caravelli@ircc.it</email>
          </address>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carnevale Schianca</surname>
            <given-names>Fabrizio</given-names>
          </name>
          <address>
            <email>fabrizio.carnevale@ircc.it</email>
          </address>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>D&#x2019;Ambrosio</surname>
            <given-names>Lorenzo</given-names>
          </name>
          <address>
            <email>lorenzo.dambrosio@ircc.it</email>
          </address>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tolomeo</surname>
            <given-names>Francesco</given-names>
          </name>
          <address>
            <email>francesco.tolomeo@tiscali.it</email>
          </address>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Boccone</surname>
            <given-names>Paola</given-names>
          </name>
          <address>
            <email>paola.boccone@ircc.it</email>
          </address>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Manca</surname>
            <given-names>Antonio</given-names>
          </name>
          <address>
            <email>antonio.manca@ircc.it</email>
          </address>
          <xref ref-type="aff" rid="Aff15"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>De Rosa</surname>
            <given-names>Giovanni</given-names>
          </name>
          <address>
            <email>gderosa@mauriziano.it</email>
          </address>
          <xref ref-type="aff" rid="Aff16"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nuzzo</surname>
            <given-names>Annamaria</given-names>
          </name>
          <address>
            <email>annamaria.nuzzo@ircc.it</email>
          </address>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Aglietta</surname>
            <given-names>Massimo</given-names>
          </name>
          <address>
            <email>massimo.aglietta@ircc.it</email>
          </address>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Grignani</surname>
            <given-names>Giovanni</given-names>
          </name>
          <address>
            <email>giovanni.grignani@ircc.it</email>
          </address>
          <xref ref-type="aff" rid="Aff14"/>
        </contrib>
        <aff id="Aff14"><label/>Division of Oncology, Candiolo Cancer Institute, FPO, IRCCS, University of Torino Medical School, Candiolo, Italy </aff>
        <aff id="Aff15"><label/>Radiology Unit, Candiolo Cancer Institute, FPO, IRCCS, Candiolo, Italy </aff>
        <aff id="Aff16"><label/>Division of Surgical Pathology, Ospedale Umberto I Ordine Mauriziano, Torino, Italy </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>14</day>
        <month>8</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>14</day>
        <month>8</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>7</volume>
      <elocation-id>529</elocation-id>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>2</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>4</day>
          <month>8</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Rota Scalabrini et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Vanishing bile duct syndrome has been associated with different pathologic conditions (adverse drug reactions, autoimmune diseases, graft versus host disease, and cancer). Though its causes are unknown, an immune-related pathogenesis is the most likely one. Vanishing bile duct syndrome can evolve to hepatic failure and, eventually, to death. The treatment is uncertain, but it needs the resolution of the underlying pathologic condition.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We describe the association of Hodgkin&#x2019;s lymphoma with a syndrome characterized by cholestasis, aminotransferase elevation and an histological picture of bile duct loss. All other causes of hepatic function impairment were excluded (in particular, drugs, viral and autoimmune related diseases) eventually leading to the diagnosis of vanishing bile duct syndrome. Despite the fact that the dysfunction is not caused by hepatic Hodgkin&#x2019;s lymphoma involvement, liver impairment can limit the optimal therapy of Hodgkin&#x2019;s lymphoma. A treatment consisting of ursodeoxycholic acid, prednisone, and full dose chemotherapy restored hepatic function and achieved complete and long-lasting remission of Hodgkin&#x2019;s lymphoma.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>We reviewed all case reports showing that vanishing bile duct syndrome is a dismal paraneoplastic syndrome being fatal in a high proportion of patients if not adequately treated. Indeed, this syndrome requires both an early recognition and an appropriate aggressive treatment consisting of full dose upfront chemotherapy which is the only way to achieve a resolution of the vanishing bile duct syndrome. Delayed or reduced intensity treatments unfavorably correlate with survival.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Vanishing bile duct syndrome</kwd>
        <kwd>Ductopenia</kwd>
        <kwd>Hodgkin&#x2019;s lymphoma</kwd>
        <kwd>Ursodeoxycholic acid</kwd>
        <kwd>Paraneoplastic syndrome</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p>Vanishing bile duct syndrome (VBDS) is defined as an intrahepatic cholestasis with paucity of interlobular bile ducts [<xref ref-type="bibr" rid="CR1">1</xref>]. The cause is unknown and it has been associated with different pathologic conditions: adverse drug reactions, autoimmune diseases, graft versus host disease, and cancer. These associations make the immune-mediated pathogenesis the most likely one. Histology is characterized by marked cholestasis without evidences of an accompanying hepatitis, but with a characteristic loss of bile ducts in the portal tracts. Clinical outcome is hepatic failure unless the underlying disease can be appropriately cured. We present a case of a VBDS that heralded the successive diagnosis of Hodgkin&#x2019;s lymphoma (HL).</p>
    </sec>
    <sec id="Sec2">
      <title>Case presentation</title>
      <p>A 42-year-old Caucasian woman was admitted to an infectious disease unit because of jaundice and fever. Her medical past history was unremarkable except for a mild allergy to cat hair. On admission her abnormal chemical tests were: total and direct bilirubin of 18.3 milligrams/deciliter (mg/dL) and 15.3&#xA0;mg/dL, respectively (normal value up to 1.3 and 0.4&#xA0;mg/dL, respectively); aspartate (AST) and alanine aminotransferase (ALT), 151 and 322, respectively (normal value up to 35 units/liter (U/L) and 40 U/L, respectively); alkaline phosphatase (ALP) 322 U/L (normal value up to 240 U/L); gamma-glutamyl transpeptidase (GGT) 482 U/L (normal value up to 35 U/L). Blood counts were normal except for leukocytosis (15170/&#x3BC;L). The patient was not taking any drug, and an extensive infectious disease work-up was negative. Particularly, hepatotropic viruses such as hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) were excluded as well as Epstein-Barr virus (EBV) and cytomegalovirus (CMV). A computed tomography (CT) scan showed enlarged mediastinal lymph nodes without any abdominal pathological feature, and no sign of biliary tract dilatation. At that time, the patient was referred to our center, and a mediastinal biopsy was performed showing a picture of classic HL of nodular sclerosis histotype. Furthermore, the most common antibodies responsible for autoimmune hepatitis (ANA - antinuclear antibodies, ASMA &#x2013; anti-smooth-muscle antibodies, anti-LKM1 &#x2013; anti-liver-kidney microsomal type 1, anti-SLA - antibodies against soluble liver antigen, AMA - antimitochondrial antibody, antiphospholipid antibodies) were evaluated without any pathological findings. Since biochemical cholestasis had worsened (total bilirubin 33.8&#xA0;mg/dL), a hepatic biopsy was performed showing marked cellular and canalicular perivenous cholestasis. Remarkably, bile ducts were absent (Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>) in all seven portal tracts examined and no sign of HL could be detected in a picture consistent with a VBDS [<xref ref-type="bibr" rid="CR1">1</xref>]. Bone marrow trephine was negative. We also carried out a positron emission tomography (PET) scan that showed increased 18&#xA0;F-fluoro-deoxy-glucose (18&#xA0;F-FDG) uptake in multiple mediastinal lymph nodes defining a stage IIB HL. She was started on ursodeoxycholic acid (UDCA) (1350&#xA0;mg daily) and prednisone (50&#xA0;mg daily). A dramatic improvement of her clinical and biochemical conditions occurred with a decreased total bilirubin to 10&#xA0;mg/dL. At this point, doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy was delivered and, after 4&#xA0;cycles, we performed interim restaging with the PET scan showing a complete response. Therefore, she subsequently received two additional cycles of ABVD with a complete response confirmed after six cycles. Despite the fact that total bilirubin was increased at the time of the first cycle, we delivered a full dose of doxorubicin and vinblastine. At completion, prednisone was tapered and UDCA interrupted. The patient declined to receive a hepatic biopsy at the end of chemotherapy. Six years later, she is still in complete remission with a thoroughly normal hepatic function.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Paraffin embedded section of the liver biopsy stained in hematoxylin-eosin showing fibrotic portal spaces without evidence of biliary interlobular ducts.</bold> (Panel <bold>A</bold> 5x magnification, Panel <bold>B</bold> 20x magnification, Panel <bold>C</bold> 40x magnification).</p></caption><graphic xlink:href="13104_2014_3066_Fig1_HTML" id="d30e334"/></fig></p>
    </sec>
    <sec id="Sec3" sec-type="conclusions">
      <title>Conclusion</title>
      <p>Several conditions may cause jaundice in HL. Biliary obstruction secondary to lymph nodes enlargement, hemolysis, hepatotropic and other viruses (e.g. CMV) are among the most common causes. Hepatic direct involvement by HL is a relatively rare, but well known complication [<xref ref-type="bibr" rid="CR2">2</xref>]. The association of cholestatic jaundice and hepatic bile duct loss (a picture called &#x201C;ductopenia&#x201D;) in HL has been described in other 39 other cases in the literature (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). This is a severe complication with a high rate of death in a neoplastic disease otherwise curable in more than 80% of patients. In 18 HL patients steroid plus lymphoma treatment (both chemotherapy and radiotherapy) was described to improve hepatic function and eventually led to complete remission of both hepatic and Hodgkin&#x2019;s diseases. All other cases died because of hepatic failure. A clear pathogenetic relationship between HL and VBDS cannot be identified. Nevertheless, the concomitance of the two diseases and the case reported by Allory [<xref ref-type="bibr" rid="CR3">3</xref>] makes the hypothesis of VBDS likely to be a paraneoplastic manifestation of HL. Furthermore, Bruguera [<xref ref-type="bibr" rid="CR4">4</xref>] has shown hepatic sinusoidal dilatation (a feature of VBDS) in 90% of patients presenting systemic symptoms (so called B symptoms) without any evidence of direct liver involvement by the lymphoma. This datum suggests the role of HL as the trigger event of cytokine-mediated hepatic damage [<xref ref-type="bibr" rid="CR5">5</xref>]. There is evidence that biliary epithelial cells [<xref ref-type="bibr" rid="CR6">6</xref>] express major histocompatibility complex (MHC) antigens (both class I and II) as well as adhesion molecules like intercellular adhesion molecule 1 (ICAM-1) in response to cytokines produced by HL. In this context, both types of molecules may contribute to adhesion and cytotoxicity due to T lymphocytes. As of today, there is no recognized treatment for VBDS. We, as well as other authors, used UDCA because of its demonstrated activity in primary biliary cirrhosis. Indeed, beneficial effects of treatment with UDCA have been reported in other immune-mediated disease involving the biliary tree as primary sclerosing cholangitis [<xref ref-type="bibr" rid="CR7">7</xref>] or hepatic involvement by graft versus host disease [<xref ref-type="bibr" rid="CR8">8</xref>]. UDCA acts at three levels: increasing the expression of transporter proteins into the canalicular membrane, inhibiting apoptosis induced by toxic bile acids, and altering the composition of the micelles of bile acids [<xref ref-type="bibr" rid="CR7">7</xref>].<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Summary of all cases reported in the literature regarding vanishing bile duct syndrome in lymphomas</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Author</th><th>Number of patients</th><th>Hodgkin lymphoma treatment*</th><th>Dosage</th><th>Ursodeoxycholic acid</th><th>Outcome</th></tr></thead><tbody><tr><td>Bouroncle B. [<xref ref-type="bibr" rid="CR9">9</xref>]</td><td align="center">2</td><td align="center">Yes</td><td align="center">Full</td><td align="center">Unknown</td><td align="center">Hepatic failure</td></tr><tr><td/><td align="center"/><td align="center">Yes</td><td align="center">Reduced</td><td align="center"/><td align="center">Hepatic failure</td></tr><tr><td>Juniper K. [<xref ref-type="bibr" rid="CR10">10</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Reduced</td><td align="center">Unknown</td><td align="center">Hepatic failure</td></tr><tr><td>Groth C. [<xref ref-type="bibr" rid="CR11">11</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">Unknown</td><td align="center">Hepatic failure</td></tr><tr><td>Perera D.R. [<xref ref-type="bibr" rid="CR12">12</xref>]</td><td align="center">3</td><td align="center">Yes</td><td align="center">Full</td><td align="center">Unknown</td><td align="center">Hepatic failure</td></tr><tr><td/><td align="center"/><td align="center">Yes</td><td align="center">Full</td><td align="center">Unknown</td><td align="center">Cure</td></tr><tr><td/><td align="center"/><td align="center">Yes</td><td align="center">Full</td><td align="center">Unknown</td><td align="center">Cure</td></tr><tr><td>Piken E.P. [<xref ref-type="bibr" rid="CR13">13</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">Unknown</td><td align="center">Unknown</td></tr><tr><td>Trewby P.N. [<xref ref-type="bibr" rid="CR14">14</xref>]</td><td align="center">4</td><td align="center">Yes</td><td align="center">Full</td><td align="center">Unknown</td><td align="center">Cure</td></tr><tr><td/><td align="center"/><td align="center">Yes</td><td align="center">Full</td><td align="center">Unknown</td><td align="center">Cure</td></tr><tr><td/><td align="center"/><td align="center">Yes</td><td align="center">Full</td><td align="center">Unknown</td><td align="center">Unknown</td></tr><tr><td/><td align="center"/><td align="center">No</td><td align="center">No</td><td align="center">Unknown</td><td align="center">Unknown</td></tr><tr><td>Lieberman D.A. [<xref ref-type="bibr" rid="CR15">15</xref>]</td><td align="center">1</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">Respiratory arrest</td></tr><tr><td>Birrer M.J. [<xref ref-type="bibr" rid="CR16">16</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">Unknown</td><td align="center">Sepsis</td></tr><tr><td>Hubscher S.G. [<xref ref-type="bibr" rid="CR1">1</xref>]</td><td align="center">3</td><td align="center">Yes</td><td align="center">Reduced</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td>Jansen P.L.M. [<xref ref-type="bibr" rid="CR17">17</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">Late</td><td align="center">Hepatic failure</td></tr><tr><td>Warner A.S. [<xref ref-type="bibr" rid="CR18">18</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Cure</td></tr><tr><td>Gottrand F. [<xref ref-type="bibr" rid="CR19">19</xref>]</td><td align="center">1</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td>Crosbie O.M. [<xref ref-type="bibr" rid="CR20">20</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">Yes</td><td align="center">Cure</td></tr><tr><td>De Medeiros B.C. [<xref ref-type="bibr" rid="CR21">21</xref>]</td><td align="center">2</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td/><td align="center"/><td align="center"/><td align="center">Full</td><td align="center"/><td align="center"/></tr><tr><td>Yalcin S. [<xref ref-type="bibr" rid="CR22">22</xref>]</td><td align="center">2</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td/><td align="center"/><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Cure</td></tr><tr><td>Dourakis S.P. [<xref ref-type="bibr" rid="CR23">23</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Reduced</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td>Yusuf M.A. [<xref ref-type="bibr" rid="CR24">24</xref>]</td><td align="center">1</td><td align="center">No</td><td align="center">No</td><td align="center">Late</td><td align="center">Hepatic failure</td></tr><tr><td>Rossini M.S. [<xref ref-type="bibr" rid="CR25">25</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td>Allory Y. [<xref ref-type="bibr" rid="CR3">3</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">Yes</td><td align="center">Cure</td></tr><tr><td>Ozkan A. [<xref ref-type="bibr" rid="CR26">26</xref>]</td><td align="center">1</td><td align="center">No</td><td align="center">No</td><td align="center">Late</td><td align="center">Hepatic failure</td></tr><tr><td>Ripoll C. [<xref ref-type="bibr" rid="CR27">27</xref>]</td><td align="center">2</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td/><td align="center"/><td align="center">Yes</td><td align="center">Full</td><td align="center">Yes</td><td align="center">Cure</td></tr><tr><td>Komurcu S. [<xref ref-type="bibr" rid="CR28">28</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td>Liangpunsakul S. [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Cure</td></tr><tr><td>Guliter S. [<xref ref-type="bibr" rid="CR30">30</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">Late</td><td align="center">Hepatic failure</td></tr><tr><td>C&#xF3;rdoba Iturriagagoitia A. [<xref ref-type="bibr" rid="CR31">31</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Cure</td></tr><tr><td>Han W.S. [<xref ref-type="bibr" rid="CR32">32</xref>]</td><td align="center">1</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">Recurrent Hodgkin&#x2019;s Lymphoma</td></tr><tr><td>Schmitt A. [<xref ref-type="bibr" rid="CR33">33</xref>]</td><td align="center">1</td><td align="center">No</td><td align="center">No</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td>Barta S.K. [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Cure</td></tr><tr><td>DeBenedet A.T. [<xref ref-type="bibr" rid="CR35">35</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Reduced</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td>Leeuwenburgh I. [<xref ref-type="bibr" rid="CR36">36</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Reduced</td><td align="center">No</td><td align="center">Cure</td></tr><tr><td>Pass A.K. [<xref ref-type="bibr" rid="CR37">37</xref>]</td><td align="center">2</td><td align="center">Yes</td><td align="center">Reduced</td><td align="center">Yes</td><td align="center">Cure</td></tr><tr><td/><td align="center"/><td align="center">Yes</td><td align="center">Reduced</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td>Ballonoff A. [<xref ref-type="bibr" rid="CR38">38</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Cure</td></tr><tr><td>Umit H. [<xref ref-type="bibr" rid="CR39">39</xref>]</td><td align="center">1</td><td align="center">Unknown</td><td align="center">Unknown</td><td align="center">Unknown</td><td align="center">Unknown</td></tr><tr><td>Gill R.M. [<xref ref-type="bibr" rid="CR40">40</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Reduced</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td>Foramiti S. [<xref ref-type="bibr" rid="CR41">41</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">Yes</td><td align="center">Hepatic failure</td></tr><tr><td>Gagnon MF [<xref ref-type="bibr" rid="CR42">42</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Cure</td></tr><tr><td>Wong KM [<xref ref-type="bibr" rid="CR43">43</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Cure</td></tr><tr><td>Aleem A1 [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td>Nader K [<xref ref-type="bibr" rid="CR45">45</xref>]</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">No</td><td align="center">Hepatic failure</td></tr><tr><td>Our patient</td><td align="center">1</td><td align="center">Yes</td><td align="center">Full</td><td align="center">Yes</td><td align="center">Cure</td></tr></tbody></table><table-wrap-foot><p>*either chemotherapy or radiotherapy.</p></table-wrap-foot></table-wrap></p>
      <p>In the present report we stress two aspects. First, the therapeutic choice to use high-dose of UDCA [<xref ref-type="bibr" rid="CR46">46</xref>] and prednisone which rapidly determined an improvement of our patients. Secondly, although still icteric, we delivered a full dose chemotherapy achieving a sustained complete remission that, in a paraneoplastic disease, is the most important result. An appropriate aggressive treatment (either chemotherapy or radiotherapy) was reported in all patients who were, in the end, cured (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). Notwithstanding, several good reasons stand for a dose reduction in both doxorubicin and vinblastine in a jaundiced patient, we emphasize the &#x201C;full dose&#x201D; chemotherapy choice. ABVD chemotherapy is conceived as a 2-weekly treatment and, therefore, 25&#xA0;mg/m<sup>2</sup> doxorubicin was felt appropriate regardless of jaundice. Indeed, it is half the dose used in other combinations (<italic>e.g.</italic> CHOP regimen - Cyclophosphamide, Doxorubicin, Vincristine, Prednisone or CODOX-M/IVAC &#x2013; Cyclophosphamide, Vincristine, Doxorubicin, Methotrexate, Ifosfamide, Etoposide, Cytarabine [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]). Moreover, it is well known that the ABVD dose intensity affects the HL outcome [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. Lastly, only 1 out of 8 (12%) patients receiving an upfront reduced chemotherapy overcame the vanishing bile duct, compared to 51% (17/33) of patients treated with upfront full dose chemotherapy (see Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). In these patients the efficacious treatment of the lymphoma preceded the hepatic improvement and, ultimately, the cure.</p>
      <p>This case report demonstrates that in the presence of a histological diagnosis of HL associated with signs of cholestasis and liver function impairment without gross liver involvement or biliary tract dilatation, the prompt treatment of the underlying disease in association with high doses of UDCA is crucial. Indeed, data available in the literature strengthen the theory that the therapy able to restore liver function is full dose chemotherapy only. In this setting, waiting for the histological confirmation of VBDS may be harmful because a delayed start might be detrimental to patient outcome. Indeed, liver impairment could evolve to liver insufficiency and eventually to death as is clearly outlined in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.</p>
      <p>In conclusion, VBDS must be considered a rare but possible complication of HL. Its prompt recognition and appropriate treatment can dramatically affect patients&#x2019; outcome.</p>
    </sec>
    <sec id="Sec4">
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>All authors declared no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>DRS, DC, FCS, LD, FT, PB, AN, MA, GG were involved in the differential diagnosis of VBDS, in the clinical care of the patient and in the data collection and report. AM performed the biopsies. GD performed the histological diagnoses. All authors revised the manuscript and approved the final version for submission.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>All authors acknowledge the nurses who helped in the clinical care of this patient. We thank Ms Elisa De Boni and Ms Hannah Gregory for language editing. None of the authors received funding for writing this article.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hubscher</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Lumley</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Elias</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Vanishing bile duct syndrome: a possible mechanism for intrahepatic cholestasis in Hodgkin&#x2019;s lymphoma</article-title>
          <source>Hepatology</source>
          <year>1993</year>
          <volume>17</volume>
          <fpage>70</fpage>
          <lpage>77</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.1840170114</pub-id>
          <pub-id pub-id-type="pmid">7678577</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cervantes</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Briones</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bruguera</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Font</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Grau</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Rozman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Montserrat</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Hodgkin&#x2019;s disease presenting as cholestatic febrile illness and main characteristics in a series of 421 patients</article-title>
          <source>Ann Hematol</source>
          <year>1996</year>
          <volume>72</volume>
          <fpage>357</fpage>
          <lpage>360</lpage>
          <pub-id pub-id-type="doi">10.1007/s002770050186</pub-id>
          <pub-id pub-id-type="pmid">8767104</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Allory</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Metreu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zafrani</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Paraneoplastic vanishing bile duct syndrome in a case of Hodgkin&#x2019;s disease</article-title>
          <source>Ann Pathol</source>
          <year>2000</year>
          <volume>20</volume>
          <fpage>52</fpage>
          <lpage>55</lpage>
          <pub-id pub-id-type="pmid">10648987</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bruguera</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Caballero</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Carreras</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Aymerich</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rodes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rozman</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Hepatic sinusoidal dilatation in Hodgkin&#x2019;s disease</article-title>
          <source>Liver</source>
          <year>1987</year>
          <volume>7</volume>
          <fpage>76</fpage>
          <lpage>80</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0676.1987.tb00320.x</pub-id>
          <pub-id pub-id-type="pmid">3613878</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reynoso-Paz</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Coppel</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Ansari</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>Gershwin</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Vanishing bile duct syndromes: considerations of the immuno-biology of autoimmune biliary diseases</article-title>
          <source>IMAJ</source>
          <year>1999</year>
          <volume>1</volume>
          <fpage>37</fpage>
          <lpage>48</lpage>
          <pub-id pub-id-type="pmid">11370120</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Adams</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Hubscher</surname>
              <given-names>SG</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rothlein</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Neuberger</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Intercellular adhesion molecule 1 on liver allografts during rejection</article-title>
          <source>Lancet</source>
          <year>1989</year>
          <volume>2</volume>
          <fpage>1122</fpage>
          <lpage>1125</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(89)91489-X</pub-id>
          <pub-id pub-id-type="pmid">2572848</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pusl</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Beuers</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Ursodexycholic acid treatment of vanishing bile duct syndromes</article-title>
          <source>World J Gastroenterol</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>3487</fpage>
          <lpage>3495</lpage>
          <pub-id pub-id-type="pmid">16773706</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fried</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Murakami</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Fisher</surname>
              <given-names>LD</given-names>
            </name>
            <name>
              <surname>Willson</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Sullivan</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>McDonald</surname>
              <given-names>GB</given-names>
            </name>
          </person-group>
          <article-title>Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver</article-title>
          <source>Ann Intern Med</source>
          <year>1992</year>
          <volume>116</volume>
          <fpage>624</fpage>
          <lpage>629</lpage>
          <pub-id pub-id-type="doi">10.7326/0003-4819-116-8-624</pub-id>
          <pub-id pub-id-type="pmid">1546861</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bouroncle</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Old</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Vazques</surname>
              <given-names>AG</given-names>
            </name>
          </person-group>
          <article-title>Pathogenesis of jaundice in Hodgkin&#x2019;s disease</article-title>
          <source>Arch Intern Med</source>
          <year>1962</year>
          <volume>110</volume>
          <fpage>872</fpage>
          <lpage>883</lpage>
          <pub-id pub-id-type="doi">10.1001/archinte.1962.03620240054009</pub-id>
          <pub-id pub-id-type="pmid">14014505</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Juniper</surname>
              <given-names>K</given-names>
              <suffix>Jr</suffix>
            </name>
          </person-group>
          <article-title>Prolonged severe obstructive jaundice in Hodgkin&#x2019;s disease</article-title>
          <source>Gastroenterology</source>
          <year>1963</year>
          <volume>44</volume>
          <fpage>199</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="pmid">13958086</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Groth</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Hellstr&#xF6;m</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Hofvendahl</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nordenstam</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wengle</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Diagnosis of malignant lymphoma at laparotomy disclosing intrahepatic cholestasis</article-title>
          <source>Acta Chir Scand</source>
          <year>1972</year>
          <volume>138</volume>
          <fpage>186</fpage>
          <lpage>189</lpage>
          <pub-id pub-id-type="pmid">4556480</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perera</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Greene</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Fenster</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
          <article-title>Cholestasis associated with extrabiliary Hodgkin&#x2019;s disease</article-title>
          <source>Gastroenterology</source>
          <year>1974</year>
          <volume>67</volume>
          <fpage>680</fpage>
          <lpage>685</lpage>
          <pub-id pub-id-type="pmid">4412423</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piken</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Abaraham</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Hepner</surname>
              <given-names>GW</given-names>
            </name>
          </person-group>
          <article-title>Investigation of a patient with Hodgkin&#x2019;s disease and cholestasis</article-title>
          <source>Gastroenterology</source>
          <year>1979</year>
          <volume>77</volume>
          <fpage>145</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="pmid">447013</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Trewby</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Portmann</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Brinkley</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Williams</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Liver disease as presenting manifestation of Hodgkin&#x2019;s disease</article-title>
          <source>Q J Med</source>
          <year>1979</year>
          <volume>48</volume>
          <fpage>137</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="pmid">482587</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lieberman</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Intrahepatic cholestasis due to Hodgkin&#x2019;s disease: an elusive diagnosis</article-title>
          <source>J Clin Gastroenterol</source>
          <year>1986</year>
          <volume>8</volume>
          <fpage>304</fpage>
          <lpage>307</lpage>
          <pub-id pub-id-type="doi">10.1097/00004836-198606000-00022</pub-id>
          <pub-id pub-id-type="pmid">3734366</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Birrer</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Young</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Differential diagnosis of jaundice in lymphoma patients</article-title>
          <source>Semin Liver Dis</source>
          <year>1987</year>
          <volume>7</volume>
          <fpage>269</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="doi">10.1055/s-2008-1040582</pub-id>
          <pub-id pub-id-type="pmid">3317863</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jansen</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>van der Lelie</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Intrahepatic cholestasis and biliary cirrhosis associated with Hodgkin&#x2019;s disease</article-title>
          <source>Neth J Med</source>
          <year>1994</year>
          <volume>44</volume>
          <fpage>99</fpage>
          <lpage>102</lpage>
          <pub-id pub-id-type="pmid">8202211</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Warner</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Whitcomb</surname>
              <given-names>FF</given-names>
            </name>
          </person-group>
          <article-title>Extrahepatic Hodgkin&#x2019;s disease and cholestasis</article-title>
          <source>Am J Gastroenterol</source>
          <year>1994</year>
          <volume>89</volume>
          <fpage>940</fpage>
          <lpage>941</lpage>
          <pub-id pub-id-type="pmid">8198110</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gottrand</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cullu</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Mazingue</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Nelken</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Lecomte-Houcke</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Farriaux</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
          <article-title>Intrahepatic cholestasis related to vanishing bile duct syndrome in Hodgkin&#x2019;s disease</article-title>
          <source>J Pediatr Gastroenterol Nutr</source>
          <year>1997</year>
          <volume>24</volume>
          <fpage>430</fpage>
          <lpage>433</lpage>
          <pub-id pub-id-type="doi">10.1097/00005176-199704000-00013</pub-id>
          <pub-id pub-id-type="pmid">9144127</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crosbie</surname>
              <given-names>OM</given-names>
            </name>
            <name>
              <surname>Crown</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Nolan</surname>
              <given-names>NPM</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hegarty</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
          <article-title>Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin&#x2019;s disease</article-title>
          <source>Hepatology</source>
          <year>1997</year>
          <volume>26</volume>
          <fpage>5</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.510260101</pub-id>
          <pub-id pub-id-type="pmid">9214445</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Medeiros</surname>
              <given-names>BC</given-names>
            </name>
            <name>
              <surname>Lacerda</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Telles</surname>
              <given-names>JEQ</given-names>
            </name>
            <name>
              <surname>da Silva</surname>
              <given-names>JAS</given-names>
            </name>
            <name>
              <surname>de Medeiros</surname>
              <given-names>CS</given-names>
            </name>
          </person-group>
          <article-title>Cholestasis secondary to Hodgkin&#x2019;s disease: report of 2 cases of vanishing bile duct syndrome</article-title>
          <source>Haematologica</source>
          <year>1998</year>
          <volume>83</volume>
          <fpage>1038</fpage>
          <lpage>1040</lpage>
          <pub-id pub-id-type="pmid">9864926</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yalcin</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kars</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sokmensuer</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Atahan</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Extrahepatic Hodgkin&#x2019;s disease with intrahepatic cholestasis: report of two cases</article-title>
          <source>Oncology</source>
          <year>1999</year>
          <volume>57</volume>
          <fpage>83</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="doi">10.1159/000012005</pub-id>
          <pub-id pub-id-type="pmid">10394130</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dourakis</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Tzemanachis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Deutsch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kafiri</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hadziyannis</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
          <article-title>Fulminant hepatic failure as presenting paraneoplastic manifestation of Hodgkin&#x2019;s disease</article-title>
          <source>Eur J Gastroenterol Hepatol</source>
          <year>1999</year>
          <volume>11</volume>
          <fpage>1055</fpage>
          <lpage>1058</lpage>
          <pub-id pub-id-type="doi">10.1097/00042737-199909000-00019</pub-id>
          <pub-id pub-id-type="pmid">10503847</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yusuf</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Elias</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hubscher</surname>
              <given-names>SG</given-names>
            </name>
          </person-group>
          <article-title>Jaundice caused by the vanishing bile duct syndrome in a child with Hodgkin&#x2019;s lymphoma</article-title>
          <source>J Pediatr Hematol Oncol</source>
          <year>2000</year>
          <volume>22</volume>
          <fpage>154</fpage>
          <lpage>157</lpage>
          <pub-id pub-id-type="doi">10.1097/00043426-200003000-00014</pub-id>
          <pub-id pub-id-type="pmid">10779030</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rossini</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Lorand-Metze</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>GB</given-names>
            </name>
            <name>
              <surname>De Souza</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
          <article-title>Vanishing bile duct syndrome in Hodgkin&#x2019;s disease: case report</article-title>
          <source>Sao Paulo Med J</source>
          <year>2000</year>
          <volume>118</volume>
          <fpage>154</fpage>
          <lpage>157</lpage>
          <pub-id pub-id-type="pmid">11018850</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ozkan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yoruk</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Celkan</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Apak</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yildiz</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Ozbay</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>The vanishing bile duct syndrome in a child with Hodgkin&#x2019;s disease</article-title>
          <source>Med Pediatr Oncol</source>
          <year>2001</year>
          <volume>36</volume>
          <fpage>398</fpage>
          <lpage>399</lpage>
          <pub-id pub-id-type="doi">10.1002/mpo.1096</pub-id>
          <pub-id pub-id-type="pmid">11241447</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ripoll</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Carretero</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Sabir</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Alvarez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Marrupe</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Banares</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic cholestasis associated with progressive ductopenia in two patients with Hodgkin&#x2019;s disease</article-title>
          <source>Gastroenterol Hepatol</source>
          <year>2002</year>
          <volume>25</volume>
          <fpage>313</fpage>
          <lpage>315</lpage>
          <pub-id pub-id-type="doi">10.1016/S0210-5705(02)79026-2</pub-id>
          <pub-id pub-id-type="pmid">11985802</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>K&#xF6;m&#xFC;rc&#xFC;</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ozet</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Altundag</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Arpaci</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Ozt&#xFC;rk</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Celasun</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Tezcan</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Vanishing bile duct syndrome occurring after high-dose chemotherapy and autologous peripheral stem cell transplantation in a patient with Hodgkin&#x2019;s disease</article-title>
          <source>Ann Hematol</source>
          <year>2002</year>
          <volume>81</volume>
          <fpage>57</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.1007/s00277-001-0406-7</pub-id>
          <pub-id pub-id-type="pmid">11807639</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liangpunsakul</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kwo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Koukoulis</surname>
              <given-names>GK</given-names>
            </name>
          </person-group>
          <article-title>Hodgkin&#x2019;s disease presenting as cholestatic hepatitis with prominent ductal injury</article-title>
          <source>Eur J Gastroenterol Hepatol</source>
          <year>2002</year>
          <volume>14</volume>
          <fpage>323</fpage>
          <lpage>327</lpage>
          <pub-id pub-id-type="doi">10.1097/00042737-200203000-00019</pub-id>
          <pub-id pub-id-type="pmid">11953700</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guliter</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Erdem</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Isik</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yamac</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Uluoglu</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) in Hodgkin&#x2019;s disease: report of a case</article-title>
          <source>Tumori</source>
          <year>2004</year>
          <volume>90</volume>
          <fpage>517</fpage>
          <lpage>520</lpage>
          <pub-id pub-id-type="pmid">15656342</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cordoba Iturriagagoitia</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Inarrairaegui Bastarrica</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Perez de Equiza</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zozaya Urmeneta</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Martinez-Penuela</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Beloqui Perez</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Ductal regeneration in vanishing bile duct syndrome in Hodgkin&#x2019;s lymphoma</article-title>
          <source>Gastroenterol Hepatol</source>
          <year>2005</year>
          <volume>28</volume>
          <fpage>275</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="doi">10.1157/13074061</pub-id>
          <pub-id pub-id-type="pmid">15871809</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Han</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Jung</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JY</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Yeon</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Byun</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>CH</given-names>
            </name>
          </person-group>
          <article-title>Spontaneous resolution of vanishing bile duct syndrome in Hodgkin&#x2019;s lymphoma</article-title>
          <source>Korean J Hepatol</source>
          <year>2005</year>
          <volume>11</volume>
          <fpage>164</fpage>
          <lpage>168</lpage>
          <pub-id pub-id-type="pmid">15980675</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmitt</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gilden</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Saint</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Moseley</surname>
              <given-names>RH</given-names>
            </name>
          </person-group>
          <article-title>Clinical problem-solving. Empirically incorrect</article-title>
          <source>N Engl J Med</source>
          <year>2006</year>
          <volume>354</volume>
          <fpage>509</fpage>
          <lpage>514</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMcps051762</pub-id>
          <pub-id pub-id-type="pmid">16452563</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barta</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Yahalom</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Shia</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hamlin</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin&#x2019;s lymphoma</article-title>
          <source>Clin Lymphoma Myeloma</source>
          <year>2006</year>
          <volume>7</volume>
          <fpage>77</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="doi">10.3816/CLM.2006.n.044</pub-id>
          <pub-id pub-id-type="pmid">16879775</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>DeBenedet</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Berg</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Enfield</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Woodford</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Bennett</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Northup</surname>
              <given-names>PG</given-names>
            </name>
          </person-group>
          <article-title>A case of vanishing bile duct syndrome and IBD secondary to Hodgkin&#x2019;s lymphoma</article-title>
          <source>Nat Clin Pract Gastroenterol Hepatol</source>
          <year>2008</year>
          <volume>5</volume>
          <fpage>49</fpage>
          <lpage>53</lpage>
          <pub-id pub-id-type="doi">10.1038/ncpgasthep1001</pub-id>
          <pub-id pub-id-type="pmid">18174907</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leeuwenburgh</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Lugtenburg</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>van Buuren</surname>
              <given-names>HR</given-names>
            </name>
            <name>
              <surname>Zondervan</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>de Man</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Severe jaundice, due to vanishing bile duct syndrome, as presenting symptom of Hodgkin&#x2019;s lymphoma, fully reversible after chemotherapy</article-title>
          <source>Eur J Gastroenterol Hepatol</source>
          <year>2008</year>
          <volume>20</volume>
          <fpage>145</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="doi">10.1097/MEG.0b013e3282b9e6c2</pub-id>
          <pub-id pub-id-type="pmid">18188038</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pass</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>McLin</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Rushton</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Kearney</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Hastings</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Margolin</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
          <article-title>Vanishing bile duct syndrome and Hodgkin disease: a case series and review of the literature</article-title>
          <source>J Pediatr Hematol Oncol</source>
          <year>2008</year>
          <volume>30</volume>
          <fpage>976</fpage>
          <lpage>980</lpage>
          <pub-id pub-id-type="doi">10.1097/MPH.0b013e31818b37c4</pub-id>
          <pub-id pub-id-type="pmid">19131796</pub-id>
        </element-citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ballonoff</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kavanagh</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Nash</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Drabkin</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Trotter</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Costa</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rabinovitch</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Hodgkin lymphoma-related vanishing bile duct syndrome and idiopathic cholestasis: statistical analysis of all published cases and literature review</article-title>
          <source>Acta Oncol</source>
          <year>2008</year>
          <volume>47</volume>
          <fpage>962</fpage>
          <lpage>970</lpage>
          <pub-id pub-id-type="doi">10.1080/02841860701644078</pub-id>
          <pub-id pub-id-type="pmid">17906981</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Umit</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Unsal</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Tezel</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Soylu</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Pamuk</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Turgut</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Demir</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tucer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ermantas</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Cevikbas</surname>
              <given-names>U</given-names>
            </name>
          </person-group>
          <article-title>Vanishing bile duct syndrome in a patient with Hodgkin&#x2019;s lymphoma and asymptomatic hepatitis B virus infection</article-title>
          <source>Acta Gastroenterol Belg</source>
          <year>2009</year>
          <volume>72</volume>
          <fpage>277</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="pmid">19637792</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gill</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Ferrell</surname>
              <given-names>LD</given-names>
            </name>
          </person-group>
          <article-title>Vanishing bile duct syndrome associated with peripheral T cell lymphoma, not otherwise specified, arising in a posttransplant setting</article-title>
          <source>Hepatology</source>
          <year>2010</year>
          <volume>51</volume>
          <fpage>1856</fpage>
          <lpage>1857</lpage>
          <pub-id pub-id-type="doi">10.1002/hep.23614</pub-id>
          <pub-id pub-id-type="pmid">20432263</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Foramiti</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Biondini</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bigolin</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Pasca</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rossi</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Vanishing bile duct syndrome in non-Hodgkin lymphoma: a case report</article-title>
          <source>Minerva Med</source>
          <year>2011</year>
          <volume>102</volume>
          <fpage>345</fpage>
          <lpage>349</lpage>
          <pub-id pub-id-type="pmid">21959708</pub-id>
        </element-citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gagnon</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Nguyen</surname>
              <given-names>BN</given-names>
            </name>
            <name>
              <surname>Olney</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Lemieux</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Vanishing bile duct syndrome arising in a patient with T-cell-rich large B-cell lymphoma</article-title>
          <source>J Clin Oncol</source>
          <year>2013</year>
          <volume>31</volume>
          <fpage>e357</fpage>
          <lpage>e359</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2012.46.7787</pub-id>
          <pub-id pub-id-type="pmid">23733773</pub-id>
        </element-citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wong</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>CS</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>HL</given-names>
            </name>
          </person-group>
          <article-title>Hodgkin&#x2019;s lymphoma-related vanishing bile duct syndrome: a case report and literature review</article-title>
          <source>Kaohsiung J Med Sci</source>
          <year>2013</year>
          <volume>29</volume>
          <fpage>636</fpage>
          <lpage>641</lpage>
          <pub-id pub-id-type="doi">10.1016/j.kjms.2013.05.002</pub-id>
          <pub-id pub-id-type="pmid">24183359</pub-id>
        </element-citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Aleem</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Al-Katari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Alsaleh</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Alswat</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Al-Sheikh</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Vanishing bile duct syndrome in a hodgkin&#x2019;s lymphoma patient with fatal outcome despite lymphoma remission</article-title>
          <source>Saudi J Gastroenterol</source>
          <year>2013</year>
          <volume>19</volume>
          <fpage>286</fpage>
          <lpage>289</lpage>
          <pub-id pub-id-type="doi">10.4103/1319-3767.121037</pub-id>
          <pub-id pub-id-type="pmid">24195983</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nader</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mok</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kalra</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Harb</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schwarting</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ferber</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Vanishing bile duct syndrome as a manifestation of Hodgkin&#x2019;s lymphoma: a case report and review of the literature</article-title>
          <source>Tumori</source>
          <year>2013</year>
          <volume>99</volume>
          <fpage>164e</fpage>
          <lpage>168e</lpage>
          <pub-id pub-id-type="pmid">23748809</pub-id>
        </element-citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moreno</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Careno</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Cano</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gonzalez</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Idiopathic biliary ductopenia in adults without symptoms of liver disease</article-title>
          <source>N Eng J Med</source>
          <year>1997</year>
          <volume>336</volume>
          <fpage>835</fpage>
          <lpage>838</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199703203361204</pub-id>
        </element-citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fanale</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lai</surname>
              <given-names>C-M</given-names>
            </name>
            <name>
              <surname>McLaughlin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Romaguera</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Fayad</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hagemeister</surname>
              <given-names>FB</given-names>
            </name>
            <name>
              <surname>Samaniego</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rodriguez</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Neelapu</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Kwak</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Reed</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Dabaja</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Popat</surname>
              <given-names>UR</given-names>
            </name>
            <name>
              <surname>Younes</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Outcomes of nodular lymphocyte predominant Hodgkin&#x2019;s lymphoma (NLPHL) patients treated with R-CHOP [abstract]</article-title>
          <source>Blood</source>
          <year>2010</year>
          <volume>116</volume>
          <fpage>2812</fpage>
          <pub-id pub-id-type="doi">10.1182/blood-2010-02-270611</pub-id>
          <pub-id pub-id-type="pmid">20585043</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Straus</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Teruya-Feldstein</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Portlock</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Moskowitz</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Goy</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hedrick</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Zelenetz</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Noy</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma</article-title>
          <source>Cancer</source>
          <year>2003</year>
          <volume>98</volume>
          <fpage>1196</fpage>
          <lpage>1205</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.11628</pub-id>
          <pub-id pub-id-type="pmid">12973843</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Landgren</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Algernon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Axdorph</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Nilsson</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wedelin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Porwit-MacDonald</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Grimfors</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bj&#xF6;rkholm</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Hodgkin&#x2019;s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis</article-title>
          <source>Haematologica</source>
          <year>2003</year>
          <volume>88</volume>
          <fpage>438</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="pmid">12681971</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Evens</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Hutchings</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Diehl</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Treatment of Hodgkin lymphoma: the past, present, and future</article-title>
          <source>Nat Clin Pract Oncol</source>
          <year>2008</year>
          <volume>5</volume>
          <fpage>543</fpage>
          <lpage>556</lpage>
          <pub-id pub-id-type="doi">10.1038/ncponc1186</pub-id>
          <pub-id pub-id-type="pmid">18679394</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
